These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 28601236)
1. Role of cyclooxygenase-2 inhibitors in the survival outcome of colorectal cancer patients: A population-based cohort study. Huang WW; Hsieh KP; Huang RY; Yang YH Kaohsiung J Med Sci; 2017 Jun; 33(6):308-314. PubMed ID: 28601236 [TBL] [Abstract][Full Text] [Related]
2. High- versus low-dose leucovorin in the modified FOLFOX6 regimen for first-line treatment of metastatic colorectal cancer. Reynolds J; Chamberland-Tremblay A; Herrington JD; Munoz Maldonado Y; Wong L J Oncol Pharm Pract; 2017 Apr; 23(3):173-178. PubMed ID: 26786027 [TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358 [TBL] [Abstract][Full Text] [Related]
4. Survival impact of surgical resection of primary tumor in patients with stage IV colorectal cancer: results from a large population-based cohort study. Ahmed S; Leis A; Fields A; Chandra-Kanthan S; Haider K; Alvi R; Reeder B; Pahwa P Cancer; 2014 Mar; 120(5):683-91. PubMed ID: 24222180 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin. Cohen SA; Wu C; Yu M; Gourgioti G; Wirtz R; Raptou G; Gkakou C; Kotoula V; Pentheroudakis G; Papaxoinis G; Karavasilis V; Pectasides D; Kalogeras KT; Fountzilas G; Grady WM Clin Colorectal Cancer; 2016 Jun; 15(2):164-9. PubMed ID: 26702772 [TBL] [Abstract][Full Text] [Related]
6. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer. Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496 [TBL] [Abstract][Full Text] [Related]
7. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525 [TBL] [Abstract][Full Text] [Related]
8. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961 [TBL] [Abstract][Full Text] [Related]
9. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy. Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767 [TBL] [Abstract][Full Text] [Related]
10. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965 [TBL] [Abstract][Full Text] [Related]
11. Surgical Resection of Primary Tumor in Asymptomatic or Minimally Symptomatic Patients With Stage IV Colorectal Cancer: A Canadian Province Experience. Ahmed S; Fields A; Pahwa P; Chandra-Kanthan S; Zaidi A; Le D; Haider K; Reeder B; Leis A Clin Colorectal Cancer; 2015 Dec; 14(4):e41-7. PubMed ID: 26140732 [TBL] [Abstract][Full Text] [Related]
12. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971 [TBL] [Abstract][Full Text] [Related]
13. Colorectal cancer surgery in portal hypertensive patients: does adjuvant oxaliplatin affect prognosis? Madbouly KM; Hussein AM; Zeid A Dis Colon Rectum; 2013 May; 56(5):577-85. PubMed ID: 23575396 [TBL] [Abstract][Full Text] [Related]
14. Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients. Lee DW; Han SW; Cha Y; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Park JW; Ryoo SB; Jeong SY; Kang GH; Park KJ; Kim TY BMC Cancer; 2015 Oct; 15():690. PubMed ID: 26467912 [TBL] [Abstract][Full Text] [Related]
15. Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis. Kim MS; Chung M; Ahn JB; Kim CW; Cho MS; Shin SJ; Baek SJ; Hur H; Min BS; Baik SH; Kim NK J Surg Oncol; 2014 Aug; 110(2):214-21. PubMed ID: 24668581 [TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T; Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067 [TBL] [Abstract][Full Text] [Related]
17. Overcoming the challenges of primary tumor management in patients with metastatic colorectal cancer unresectable for cure and an asymptomatic primary tumor. Matsumoto T; Hasegawa S; Matsumoto S; Horimatsu T; Okoshi K; Yamada M; Kawada K; Sakai Y Dis Colon Rectum; 2014 Jun; 57(6):679-86. PubMed ID: 24807591 [TBL] [Abstract][Full Text] [Related]
18. Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients. Uncu D; Aksoy S; Çetin B; Yetişyiğit T; Özdemir N; Berk V; Dane F; Inal A; Harputluoğlu H; Budakoğlu B; Koca D; Sevinç A; Cihan S; Durnalı AG; Özkan M; Öztürk MA; Işıkdoğan A; Büyükberber S; Benekli M; Köş T; Alkış N; Karaca H; Turhal NS; Zengin N; Oncology; 2013; 84(4):240-5. PubMed ID: 23392240 [TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503 [TBL] [Abstract][Full Text] [Related]
20. Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70. Lu CS; Chang PY; Chen YG; Chen JH; Wu YY; Ho CL PLoS One; 2015; 10(9):e0138632. PubMed ID: 26382962 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]